These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 20423465)

  • 1. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
    Zhang GZ; Jiao SC; Meng ZT
    J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
    Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
    Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
    Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
    Manegold C; Gatzemeier U; von Pawel J; Pirker R; Malayeri R; Blatter J; Krejcy K
    Ann Oncol; 2000 Apr; 11(4):435-40. PubMed ID: 10847462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
    Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
    Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
    Shi X; Yu XM; Zhang YP; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
    Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
    Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
    Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
    Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
    Gervais R; Robinet G; Clément-Duchêne C; Denis F; El Kouri C; Martin P; Chouaki N; Bourayou N; Morère JF
    Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.